NKTR Nektar Therapeutics
USHealthcareAs of 2026-07-08 16:00
Why NKTR matters now
Nektar Therapeutics (NKTR) is a US stock in Healthcare. The latest InvestLog snapshot shows $71.90 with -4.01% on the session and $1.40B in market capitalization; recent performance reads 1-month -9.77% and YTD +44.23%.
The latest financial table shown here is Q1 2026, with revenue of $10.9M, net income of $-44.9M, and EPS of $-1.82. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -17.1%.
The latest indexable market news headline is "Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $151.00; recent insider activity includes ROBIN HOWARD W filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.62
P/S
21.42
EV/EBITDA
-9.55
DCF Value
$-28.60
FCF Yield
-17.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.4%
Operating Margin
-224.9%
Net Margin
-284.2%
ROE
-87.0%
ROA
-20.7%
ROIC
-17.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $10.9M | $-44.9M | $-1.82 |
| Q4 2025 | $21.8M | $-36.1M | $-1.78 |
| FY 2025 | $55.2M | $-164.1M | $-9.73 |
| Q3 2025 | $11.8M | $-35.5M | $-1.87 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$149.60
Target (Median)
$151.00
Target Range
$80.00 - $192.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.15
Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.